XML 75 R25.htm IDEA: XBRL DOCUMENT
v3.19.3

Stock-Based Compensation | 12 Months Ended
--- | ---
Jun. 30, 2019
Stock-Based Compensation [Abstract] |
Stock-Based Compensation | 17. STOCK-BASED COMPENSATION Amended and Restated Stock Incentive Plan The Company's Amended and Restated 2015 Stock Incentive Plan (the "Plan") was most recently amended and restated on November 11, 2015, after approval by shareholders. No evergreen provisions are included in the Plan. This means that the maximum number of shares issuable under the Plan is fixed and cannot be increased without shareholder approval, the plan expires by its terms upon a specified date, and no new stock options are awarded automatically upon exercise of an outstanding stock option. Shareholder approval is required for the repricing of awards or the implementation of any award exchange program. The Plan permits Net1 to grant to its employees, directors and consultants incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, performance-based awards and other awards based on its common stock. The Remuneration Committee of the Company's Board of Directors ("Remuneration Committee") administers the Plan. The total number of shares of common stock issuable under the Plan is 11,052,580. The maximum number of shares for which awards, other than performance-based awards, may be granted in any combination during a calendar year to any participant is 569,120. The maximum limits on performance-based awards that any participant may be granted during a calendar year are 569,120 shares subject to stock option awards and $20 million with respect to awards other than stock options. Shares that are subject to awards which terminate or lapse without the payment of consideration may be granted again under the Plan. Shares delivered to the Company as part or full payment for the exercise of an option or to satisfy withholding obligations upon the exercise of an option may be granted again under the Plan in the Remuneration Committee's discretion. No awards may be granted under the Plan after August 19, 2025, but awards granted on or before such date may extend to later dates. Options General Terms of Awards Option awards are generally granted with an exercise price equal to the market price of the Company's stock at the date of grant, with vesting conditioned upon the recipient's continuous service through the applicable vesting date and expire 10 years after the date of grant. The options generally become exercisable in accordance with a vesting schedule ratably over a period of three years from the date of grant. The Company issues new shares to satisfy stock option award exercises but may also use treasury shares. Valuation Assumptions The table below presents the range of assumptions used to value options granted during the year ended June 30, 2019:
| 2019 |
Expected volatility | 44 | %
Expected dividends | 0 | %
Expected life (in years) | 3 |
Risk-free rate | 2.75 | %
Nostock options were awarded during the years ended June 30, 2018 and 2017, respectively. Restricted Stock General Terms of Awards Shares of restricted stock are considered to be participating non-vested equity shares (specifically contingently returnable shares) for the purposes of calculating earnings per share (refer to Note 19) because, as discussed in more detail below, the recipient is obligated to transfer any unvested restricted stock back to the Company for no consideration and these shares of restricted stock are eligible to receive non-forfeitable dividend equivalents at the same rate as common stock. Restricted stock generally vests ratably over a three year period, with vesting conditioned upon the recipient's continuous service through the applicable vesting date and under certain circumstances, the achievement of certain performance targets, as described below. Recipients are entitled to all rights of a shareholder of the Company except as otherwise provided in the restricted stock agreements. These rights include the right to vote and receive dividends and/or other distributions. However, the restricted stock agreements generally prohibit transfer of any nonvested and forfeitable restricted stock. If a recipient ceases to be a member of the Board of Directors or an employee for any reason, all shares of restricted stock that are not then vested and nonforfeitable will be immediately forfeited and transferred to the Company for no consideration. Forfeited shares of restricted stock are available for future issuances by the Remuneration Committee. The Company issues new shares to satisfy restricted stock awards. Valuation Assumptions The fair value of restricted stock is generally based on the closing price of the Company's stock quoted on The Nasdaq Global Select Market on the date of grant. Vesting of all non-employee director shares issued prior to June 30, 2017 Grants of restricted stock to non-employee directors made during fiscal 2017, as well as those grants made in prior years, originally vested over a three-year period. After the end of fiscal 2017, the Company's board consulted with Pay Governance, an independent compensation consultant, and determined that one-year vesting of restricted stock grants is a more common compensation practice for independent directors and therefore, amended the terms of outstanding awards to vest one-year after grant. As a result of this amendment, 56,250 shares of restricted stock held by the non-employee directors as of June 30, 2017, were fully-vested during the year ended June 30, 2018. Forfeiture of restricted stock awarded in August and November 2014 that did not achieve targeted market conditions In August and November 2014, respectively, the Remuneration Committee approved an award of 127,626 and 71,530 shares of restricted stock to employees. These shares of restricted stock were scheduled to vest in full only on the date, if any, the following conditions were satisfied: (1) the closing price of the Company's common stock equals or exceeds $19.41 (subject to appropriate adjustment for any stock split or stock dividend) for a period of 30 consecutive trading days during a measurement period commencing on the date that the Company filed its Annual Report on Form 10-K for the fiscal year ended 2017 and ending on December 31, 2017 and (2) the recipient was employed by the Company on a full-time basis when the condition in (1) was met. The $19.41 price target represented a 20% increase, compounded annually, in the price of the Company's common stock on Nasdaq over the $11.23 closing price on August 27, 2014. These shares of restricted stock were forfeited during the year ended June 30, 2018, because the target market conditions were not achieved. The stock-based compensation charge related to these awards was not reversed upon forfeiture because these awards contained market conditions. The 127,626 and 71,530 shares of restricted stock were effectively forward starting knock-in barrier options with a strike price of zero. The fair value of these shares of restricted stock was calculated utilizing an adjusted Monte Carlo simulation discounted cash flow model which was developed for the purpose of the valuation of these shares. For each simulated share price path, the market share price condition was evaluated to determine whether or not the shares would vest under that simulation. The "adjustment" to the Monte Carlo simulation model incorporates a "jump diffusion" process to the standard Geometric Brownian Motion simulation, in order to capture the discontinuous share price jumps observed in the Company's share price movements on stock exchanges on which it is listed. Therefore, the simulated share price paths capture the idiosyncrasies of the observed Company share price movements. In scenarios where the shares do not vest, the final vested value at maturity is zero. In scenarios where vesting occurs, the final vested value on maturity is the share price on vesting date. The value of the grant is the average of the discounted vested values. The Company used an expected volatility of 76.01%, an expected life of approximately three years, a risk-free rate of 1.27% and no future dividends in its calculation of the fair value of the 127,626 shares of restricted stock. The Company used an expected volatility of 63.73%, an expected life of approximately three years, a risk-free rate of 1.21% and no future dividends in its calculation of the fair value of the 71,530 shares of restricted stock. Estimated expected volatility was calculated based on the Company's 30 day VWAP share price using the exponentially weighted moving average of returns. Forfeiture of restricted stock with Performance Conditions awarded in August 2015 In August 2015, the Remuneration Committee approved an award of 301,537 shares of restricted stock to employees. The shares of restricted stock awarded to employees in August 2015 were subject to time-based and performance-based vesting conditions. In order for any of the shares to have vested, the recipient had to remain employed by the Company on a full-time basis on the date that it filed its Annual Report on Form 10-K for the fiscal year ended June 30, 2018. If that condition was satisfied, then the shares would vest based on the level of Fundamental EPS the Company achieved for the fiscal year ended June 30, 2018 ("2018 Fundamental EPS"), as follows: One-third of the shares will vest if the Company achieves 2018 Fundamental EPS of $2.88; Two-thirds of the shares will vest if the Company achieves 2018 Fundamental EPS of $3.30; and All of the shares will vest if the Company achieves 2018 Fundamental EPS of $3.76. At levels of 2018 Fundamental EPS greater than $2.88 and less than $3.76, the number of shares that would have vested would be determined by linear interpolation relative to 2018 Fundamental EPS of $3.30. All shares of restricted stock have been valued utilizing the closing price of shares of the Company's common stock quoted on The Nasdaq Global Select Market on the date of grant. Any shares that did not vest in accordance with the above-described conditions would be forfeited. During the year ended June 30, 2017, the Company reversed the stock-based compensation charge recognized to date related to the 301,537 shares of restricted stock because it believed that it was unlikely that the 2018 Fundamental EPS target would be achieved due to the dilutive impact on the fundamental EPS calculation as a result of the issuance of approximately 10 million shares to the IFC in May 2016. The Company has not achieved the 2018 Fundamental EPS target and the 173,262 remaining shares that had not been forfeited as a result of terminations were forfeited during the year ended June 30, 2018. Forfeiture of 150,000 shares of restricted stock with Performance Conditions awarded in August 2016 In August 2016, the Remuneration Committee approved an award of 350,000 shares of restricted stock to executive officers. In May 2017, the Company determined to accelerate the vesting of all (200,000) of the shares of restricted stock awarded to its former CEO. The shares of restricted stock awarded to executive officers in August 2016 were subject to time-based and performance-based vesting conditions. In order for any of the shares to vest, the recipient was required to remain employed by the Company on a full-time basis on the date that it files its Annual Report on Form 10-K for the fiscal year ended June 30, 2019. If that condition is satisfied, then the shares will vest based on the level of Fundamental EPS the Company achieves for the fiscal year ended June 30, 2019 ("2019 Fundamental EPS"), as follows: One-third of the shares will vest if the Company achieves 2019 Fundamental EPS of $2.60; Two-thirds of the shares will vest if the Company achieves 2019 Fundamental EPS of $2.80; and All of the shares will vest if the Company achieves 2019 Fundamental EPS of $3.00. At levels of 2019 Fundamental EPS greater than $2.60 and less than $3.00, the number of shares that will vest will be determined by linear interpolation relative to 2019 Fundamental EPS of $2.80. All shares of restricted stock have been valued utilizing the closing price of shares of the Company's common stock quoted on The Nasdaq Global Select Market on the date of grant. Any shares that did not vest in accordance with the above-described conditions would be forfeited. During the year ended June 30, 2019, the Company reversed the stock-based compensation charge recognized related to 150,000 shares of restricted stock because the Company did not achieve the 2019 Fundamental EPS target. The 150,000 shares of restricted stock were forfeited. Market Conditions - Restricted Stock Granted in August 2017 In August 2017, the Remuneration Committee approved an award of 210,000 shares of restricted stock to executive officers. The shares of restricted stock awarded to executive officers in August 2017 are subject to a time-based vesting condition and a market condition and vest in full only on the date, if any, that the following conditions are satisfied: (1) the price of the Company's common stock must equal or exceed certain agreed VWAP levels (as described below) during a measurement period commencing on the date that it files its Annual Report on Form 10-K for the fiscal year ended 2020 and ending on December 31, 2020 and (2) the recipient is employed by the Company on a full-time basis when the condition in (1) is met. If either of these conditions is not satisfied, then none of the shares of restricted stock will vest and they will be forfeited. The $23.00 price target represents an approximate 35% increase, compounded annually, in the price of the Company's common stock on Nasdaq over the $9.38 closing price on August 23, 2017. The VWAP levels and vesting percentages related to such levels are as follows: Below $15.00 (threshold)—0% At or above $15.00 and below $19.00—33% At or above $19.00 and below $23.00—66% At or above $23.00—100% These 210,000 shares of restricted stock are effectively forward starting knock-in barrier options with multi-strike prices of zero. The fair value of these shares of restricted stock was calculated utilizing a Monte Carlo simulation model which was developed for the purpose of the valuation of these shares. For each simulated share price path, the market share price condition was evaluated to determine whether or not the shares would vest under that simulation. A standard Geometric Brownian motion process was used in the forecasting of the share price instead of a "jump diffusion" model, as the share price volatility was more stable compared to the highly volatile regime of previous years. Therefore, the simulated share price paths capture the idiosyncrasies of the observed Company share price movements. In scenarios where the shares do not vest, the final vested value at maturity is zero. In scenarios where vesting occurs, the final vested value on maturity is the share price on vesting date. The value of the grant is the average of the discounted vested values. The Company used an expected volatility of 44.0%, an expected life of approximately three years, a risk-free rate ranging between 1.275% to 1.657% and no future dividends in its calculation of the fair value of the restricted stock. The estimated expected volatility was calculated based on the Company's 30 day VWAP share price using the exponentially weighted moving average of returns. Market Conditions - Restricted Stock Granted in September 2018 In September 2018, the Remuneration Committee approved an award of 148,000 shares of restricted stock to executive officers. The 148,000 shares of restricted stock awarded to executive officers in September 2018 are subject to a time-based vesting condition and a market condition and vest in full only on the date, if any, that the following conditions are satisfied: (1) the price of the Company's common stock must equal or exceed certain agreed VWAP levels (as described below) during a measurement period commencing on the date that it files its Annual Report on Form 10-K for the fiscal year ended 2021 and ending on December 31, 2021 and (2) the recipient is employed by the Company on a full-time basis when the condition in (1) is met. If either of these conditions is not satisfied, then none of the shares of restricted stock will vest and they will be forfeited. The $23.00 price target represents an approximate 55% increase, compounded annually, in the price of the Company's common stock on Nasdaq over the $6.20 closing price on September 7, 2018. The VWAP levels and vesting percentages related to such levels are as follows: Below $15.00 (threshold)—0% At or above $15.00 and below $19.00—33% At or above $19.00 and below $23.00—66% At or above $23.00—100% The fair value of these shares of restricted stock was calculated using a Monte Carlo simulation of a stochastic volatility process. The choice of a stochastic volatility process as an extension to the standard Black Scholes process was driven by both observations of larger than expected moves in the daily time series for the Company's VWAP price, but also the observation of the strike structure of volatility (i.e. skew and smile) for out-of-the money calls and out-of-the money puts versus at-the-money options for both the Company's stock and NASDAQ futures. In scenarios where the shares do not vest, the final vested value at maturity is zero. In scenarios where vesting occurs, the final vested value on maturity is the share price on vesting date. In its calculation of the fair value of the restricted stock, the Company used an average volatility of 37.4% for the VWAP price, a discounting based on USD overnight indexed swap rates for the grant date, and no future dividends. The average volatility was extracted from the time series for VWAP prices as the standard deviation of log prices for the three years preceding the grant date. The mean reversion of volatility and the volatility of volatility parameters of the stochastic volatility process were extracted by regressing log differences against log levels of volatility from the time series for at-the-money options 30 day volatility quotes, which were available from January 2, 2018 onwards. Stock Appreciation Rights The Remuneration Committee may also grant stock appreciation rights, either singly or in tandem with underlying stock options. Stock appreciation rights entitle the holder upon exercise to receive an amount in any combination of cash or shares of common stock (as determined by the Remuneration Committee) equal in value to the excess of the fair market value of the shares covered by the right over the grant price. No stock appreciation rights have been granted. Stock option and restricted stock activity Options The following table summarizes stock option activity for the years ended June 30, 2019, 2018 and 2017:
|  |  |  | Weighted |  |  |  |
|  |  |  | Average |  |  |  | Weighted
|  |  | Weighted | Remaining |  | Aggregate |  | Average
|  |  | average | Contractual |  | Intrinsic |  | Grant
| Number of |  | exercise | Term |  | Value |  | Date Fair
| shares |  | price ($) | (in years) |  | ($'000) |  | Value ($)
Outstanding – July 1, 2016 | 2,077,524 |  | 15.92 | 3.65 |  | 926 |  | 4.15
Exercised | (321,026 | ) | 8.97 |  |  | 3,607 |  | 2.58
Expired unexercised | (474,443 | ) | 22.51 |  |  | - |  | 3.98
Forfeitures | (435,448 | ) | 17.88 |  |  | - |  | 5.34
Outstanding – June 30, 2017 | 846,607 |  | 13.87 | 3.80 |  | 486 |  | 4.21
Forfeitures | (37,333 | ) | 11.23 |  |  | - |  | 4.55
Outstanding – June 30, 2018 | 809,274 |  | 13.99 | 2.67 |  | 370 |  | 4.20
Granted – September 2018 | 600,000 |  | 6.20 | 10.00 |  | 1,212 |  | 2.02
Expired unexercised | (370,000 | ) | 19.27 |  |  |  |  | 5.00
Forfeitures | (174,695 | ) | 6.65 |  |  |  |  | 2.00
Outstanding – June 30, 2019 | 864,579 |  | 7.81 | 7.05 |  | - |  | 2.62
These options have an exercise price range of $6.20 to $11.23. The following table presents stock options vested and expected to vest as of June 30, 2019:
|  |  | Weighted |  |  |
|  | Weighted | average |  |  |
|  | average | remaining |  | Aggregate |
|  | exercise | contractual |  | intrinsic |
| Number of | price | term |  | value |
| shares | ($) | (in years) |  | ($'000) |
Vested and expected to vest – June 30, 2019 | 864,579 | 7.81 | 7.05 |  | - |
These options have an exercise price range of $6.20 to $11.23. The following table presents stock options that are exercisable as of June 30, 2019:
|  |  | Weighted |  |  |
|  |  | Average |  |  |
|  | Weighted | Remaining |  | Aggregate |
|  | average | Contractual |  | Intrinsic |
| Number of | exercise | Term |  | Value |
| shares | price ($) | (in years) |  | ($'000) |
Exercisable – June 30, 2019 | 353,579 | 10.15 | 3.84 |  | - |
No stock options became exercisable during the year ended June 30, 2019. During the year ended June 30, 2018 and 2017, 105,982 and 154,803 stock options became exercisable, respectively. No stock options were exercised during the year ended June 30, 2019 and 2018, respectively. During the year ended June 30, 2017, the Company received approximately $2.9 million from the exercise of 321,026 stock options. During the year ended June 30, 2019, 2018 and 2017, employees forfeited 174,695, 37,333 and 435,448 stock options, respectively. During the year ended June 30, 2019, 200,000 stock options awarded in August 2008 and 170,000 stock options awarded in May 2009 expired unexercised. During the year ended June 30, 2017, 474,443 stock options awarded in August 2006 expired unexercised. The Company issues new shares to satisfy stock option exercises. Restricted stock The following table summarizes restricted stock activity for the years ended June 30, 2019, 2018 and 2017:
| Number of |  |  | Weighted |
| Shares of |  |  | Average Grant |
| Restricted |  |  | Date Fair Value |
| Stock |  |  | ($'000) |
Non-vested – July 1, 2016 | 589,447 |  |  | 7,622 |
Total granted | 389,587 |  |  | 4,172 |
Granted – August 2016 | 387,000 |  |  | 4,145 |
Granted – May 2017 | 2,587 |  |  | 27 |
Total vested | (268,091 | ) |  | 2,590 |
Vested – August 2016 | (68,091 | ) |  | 694 |
Vested – June 2017 | (200,000 | ) |  | 1,896 |
Forfeitures | (205,470 | ) |  | 2,219 |
Non-vested – June 30, 2017 | 505,473 |  |  | 11,173 |
Total granted | 618,411 |  |  | 4,581 |
Granted – August 2017 | 588,594 |  |  | 4,288 |
Granted – March 2018 | 22,817 |  |  | 234 |
Granted – May 2018 | 7,000 |  |  | 59 |
Vested – August 2017 | (56,250 | ) |  | 527 |
Total forfeitures | (302,223 | ) |  | 3,222 |
Forfeitures – employee terminations | (33,635 | ) |  | 516 |
Forfeitures – August and November 2014 awards with market conditions | (95,326 | ) |  | 1,133 |
Forfeitures – August 2015 awards with performance conditions | (173,262 | ) |  | 1,573 |
Non-vested – June 30, 2018 | 765,411 |  |  | 6,162 |
Granted – September 2018 | 148,000 |  |  | 114 |
Total vested | (64,003 | ) |  | 503 |
Vested – August 2018 | (52,594 | ) |  | 459 |
Vested – March 2019 | (11,409 | ) |  | 44 |
Total forfeitures | (265,500 | ) |  | 1,060 |
Forfeitures – employee terminations | (115,500 | ) |  | 460 |
Forfeitures – August 2016 awards with performance conditions | (150,000 | ) |  | 600 |
Non-vested – June 30, 2019 | 583,908 |  |  | 3,410 |
The September 2018 grants comprise 148,000 shares of restricted stock awarded to executive officers that are subject to market and time-based vesting. The August 2017 grants comprise (i) 326,000 shares of restricted stock awarded to executive officers and employees that are subject to time-based vesting, (ii) 210,000 shares of restricted stock awarded to executive officers that are subject to market and time-based vesting as described above, and (iii) 52,594 shares of restricted stock awarded to non-employee directors. The March 2018 grant relates to an award made to the Company's new Chief Financial Officer. The May 2018 grant comprises 7,000 shares of restricted stock awarded to employees on the same terms as the 326,000 awards made. The 326,000 and 7,000 shares of restricted stock will only vest if the recipient is employed by the Company on a full-time basis on August 23, 2020. The 52,594 shares of restricted stock awarded to non-employee directors only vested if the recipient was a director on August 23, 2018. The 22,817 shares of restricted stock vest in two tranches, 11,409 vested on March 1, 2019, and 11,408 will vest on March 1, 2020, subject to the Chief Financial Officer's continued employment. The August 2016 grants comprise (i) 350,000 shares of restricted stock awarded to executive officers that are subject to performance and time-based vesting as described above and (ii) 37,000 shares of restricted stock awarded to non-employee directors. The fair value of restricted stock vested during the years ended June 30, 2019, 2018 and 2017, was $0.5 million, $0.5 million and $2.6 million, respectively. During the year ended June 30, 2019, 52,594 shares of restricted stock held by the non-employee directors and 11,409 shares of restricted stock held by the Company's Chief Financial Officer vested. During the year ended June 30, 2018, the Company determined that 56,250 shares of restricted stock held by the non-employee directors as of June 30, 2017, were fully-vested. During the year ended June 30, 2017, the Company agreed to accelerate the vesting of 200,000 shares of restricted stock granted to the Company's former Chief Executive Officer in August 2016 pursuant to the Separation Agreement signed in May 2017. During the year ended June 30, 2019, employees forfeited 115,500 shares of restricted stock upon termination which had either time-based or market conditions. In addition, an executive officer forfeited 150,000 shares of restricted stock as the performance conditions were not achieved. During the year ended June 30, 2018, employees forfeited (i) 3,000 shares of restricted stock upon termination which did not have performance or market conditions attached and (ii) 30,635 shares of restricted stock upon termination which had either market or performance conditions. In addition, executive officers and employees forfeited 95,326 shares of restricted stock as the market conditions were not achieved and forfeited 173,262 shares of restricted stock as the performance conditions were not achieved. During the year ended June 30, 2017, employees and the former Chief Executive Officer that resigned during the year ended June 30, 2017, forfeited 205,470 shares of restricted stock that had not vested. Stock-based compensation charge and unrecognized compensation cost The Company has recorded a net stock compensation charge of $0.4 million, $2.6 million and $2.0 million for the years ended June 30, 2019, 2018 and 2017, respectively, which comprised:
|  |  |  |  | Allocated to |  |  |
|  |  |  |  | cost of goods |  |  |
|  |  |  |  | sold, IT |  | Allocated to |
|  | Total |  |  | processing, |  | selling, |
|  | charge |  |  | servicing |  | general and |
|  | (reversal) |  |  | and support |  | administration |
Year ended June 30, 2019 |  |  |  |  |  |  |  |
Stock-based compensation charge | $ | 2,319 |  | $ | - | $ | 2,319 |
Reversal of stock compensation charge related to stock options |  |  |  |  |  |  |  |
and restricted stock forfeited |  | (1,926 | ) |  | - |  | (1,926 | )
Total – year ended June 30, 2019 | $ | 393 |  | $ | - | $ | 393 |
Year ended June 30, 2018 |  |  |  |  |  |  |  |
Stock-based compensation charge | $ | 2,656 |  | $ | - | $ | 2,656 |
Reversal of stock compensation charge related to restricted stock |  |  |  |  |  |  |  |
forfeited |  | (49 | ) |  | - |  | (49 | )
Total – year ended June 30, 2018 | $ | 2,607 |  | $ | - | $ | 2,607 |
Year ended June 30, 2017 |  |  |  |  |  |  |  |
Stock-based compensation charge | $ | 3,905 |  | $ | - | $ | 3,905 |
Reversal of stock compensation charge related to stock options |  |  |  |  |  |  |  |
and restricted stock forfeited |  | (1,923 | ) |  | - |  | (1,923 | )
Total – year ended June 30, 2017 | $ | 1,982 |  | $ | - | $ | 1,982 |
The stock compensation charge and reversals have been allocated to cost of goods sold, IT processing, servicing and support and selling, general and administration based on the allocation of the cash compensation paid to the relevant employees. As of June 30, 2019, the total unrecognized compensation cost related to stock options was approximately $0.8 million, which the Company expects to recognize over approximately three years. As of June 30, 2019, the total unrecognized compensation cost related to restricted stock awards was approximately $1.4 million, which the Company expects to recognize over approximately two years. Tax consequences The Company has recorded a deferred tax asset of approximately $0.2 million and $0.8 million, respectively, for the years ended June 30, 2019 and 2018. As of June 30, 2019 and 2018, the Company has a valuation allowance of approximately $0.2 million and $0.8 million, respectively, related to the deferred tax asset because it does not believe that the stock-based compensation deduction would be utilized as it does not anticipate generating sufficient taxable income in the United States. The Company deducts the difference between the market value on date of exercise by the option recipient and the exercise price from income subject to taxation in the United States.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration